{"id":231413,"date":"2026-02-15T21:06:41","date_gmt":"2026-02-16T03:06:41","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/high-relapse-rate-in-anti-caspr2-diseaseimplications-for-prolonged-immunotherapy"},"modified":"2026-02-15T21:06:41","modified_gmt":"2026-02-16T03:06:41","slug":"high-relapse-rate-in-anti-caspr2-diseaseimplications-for-prolonged-immunotherapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/high-relapse-rate-in-anti-caspr2-diseaseimplications-for-prolonged-immunotherapy","title":{"rendered":"High Relapse Rate in Anti-CASPR2 DiseaseImplications for Prolonged Immunotherapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/high-relapse-rate-in-anti-caspr2-diseaseimplications-for-prolonged-immunotherapy2.jpg\"><\/a><\/p>\n<p>This study shows a twofold higher relapse rate in anti-CASPR2 disease compared with previous studies. Prolonged immunotherapy beyond the acute stage seems needed in patients prone to relapse to prevent further relapses.<\/p>\n<hr>\n<p>Background and Objectives.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This study shows a twofold higher relapse rate in anti-CASPR2 disease compared with previous studies. Prolonged immunotherapy beyond the acute stage seems needed in patients prone to relapse to prevent further relapses. Background and Objectives.<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-231413","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=231413"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231413\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=231413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=231413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=231413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}